ID Week 2022
High-Dose Dexamethasone May Be Harmful for Patients With COVID-19
Current evidence indicates that a 6mg dose of dexamethasone daily is effective for improving COVID-19 outcomes among patients receiving supplemental oxygen.
Your search for supplemental oxygen returned 8 results
News
Actemra Approved for Treatment of Hospitalized COVID-19 Patients
Actemra (tocilizumab) is an interleukin-6 receptor antagonist.
News
FDA Authorizes Emergency Use of Kineret for Certain Hospitalized COVID-19 Patients
Kineret is an interleukin-1 receptor antagonist.
CHEST 2022
New Machine Learning Tool to Predict Pneumonia Progression Outperforms PSI
Investigators developed and validated a machine learning tool providing an early indication of disease progression in community-acquired pneumonia.
News
Asian, Black, Hispanic Patients Have Higher Pulse Oximetry Readings
Lower average oxygen delivery rates seen in association with Asian, Black, Hispanic versus White race, ethnicity
News
Olumiant Approved for COVID-19 Treatment in Hospitalized Adults
The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
News
Dapagliflozin Does Not Improve Kidney Outcomes in Hospitalized COVID-19 Cases
Investigators report findings from a secondary analysis of the DARE-19 trial, which compared dapagliflozin with placebo in patients hospitalized with COVID-19.
Drugs in the Pipeline
Tocilizumab Gets Priority Review for Treatment of Hospitalized COVID-19 Patients
The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.
